ATC35 Antigen, OX40 Antigen, ACT35, IMD16, OX40, Receptors, OX40, ACT35 antigen, TNFRSF4, CD134, TNF Receptor Superfamily Member 4, TAX Transcriptionally-Activated Glycoprotein 1 Receptor, CD134 Antigen, TXGP1L, Tumor Necrosis Factor Receptor Superfamily, Member 4, Lymphoid Activation Antigene ACT35, OX40 Homologue, Tumor necrosis factor receptor superfamily member 4, Tax-Transcriptionally Activated Glycoprotein 1 Receptor, OX40 Cell Surface Antigen, OX40L receptor


Tumor necrosis factor receptor superfamily member 4 (TNFRSF4) also known as CD134 and OX40 receptor, is the receptor for TNFSF4/OX40L/GP34. It is a costimulatory molecule implicated in long-term T-cell immunity, and acts as a receptor for human herpesvirus 6B/HHV-6B.

KO Status

RenMab: F1 (+/-)

RenLite: F0

Drug Information

Drugs in clinical trials: 19
Latest Research Phase: Phase 2 Clinical

Drug Name





Clinical Trials


PF-8600, PF-04518600

Phase 3 Clinical

Pfizer Pharmaceuticals Ltd (China)

Ovarian Neoplasms, Solid tumours, Carcinoma, Renal Cell, Carcinoma, Neoplasms, Lymphoma, Follicular, Breast Neoplasms, Leukemia, Myeloid, Acute, Carcinoma, Squamous Cell, Carcinoma, Non-Small-Cell Lung


mRNA-2416, OX40L mRNA - Moderna Therpeutics

Phase 2 Clinical

Moderna Therapeutics

Ovarian Neoplasms, Solid tumours, Lymphoma



Phase 2 Clinical

Providence Cancer Center, Agonox

Solid tumours, Head and Neck Neoplasms, Lymphoma, Large B-Cell, Diffuse, Breast Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Melanoma



Phase 2 Clinical

Kyowa Hakko Kirin Co Ltd

Abdominal Pain, Gastrointestinal Diseases, Inflammatory Bowel Diseases, Autoimmune Diseases, Colitis, Colitis, Ulcerative, Colonic Diseases, Dermatitis, Atopic, Intestinal Diseases


GSK3174998, GSK 3174998, GSK-3174998

Phase 2 Clinical

Glaxosmithkline Plc

Head and Neck Neoplasms, Neoplasms, Multiple Myeloma



Phase 2 Clinical

Agenus Inc, Ludwig Institute For Cancer Research

Carcinoma, Renal Cell, Urogenital Neoplasms, Neoplasm Metastasis



Phase 2 Clinical

Bristol-Myers Squibb Company




Phase 2 Clinical

Glenmark Pharmaceuticals Ltd

Dermatitis, Atopic



Phase 1 Clinical

Shanghai Cp Guojian Pharmaceutical Co Ltd, Bio-Thera Solutions Ltd

Solid tumours


RG-7888, MOXR-0916, RO-7021608

Phase 1 Clinical

Genentech Inc

Carcinoma, Transitional Cell, Neoplasms





The human OX40 homolog: cDNA structure, expression and chromosomal assignment of the ACT35 antigen

Latza U., Duerkop H., Schnittger S., Ringeling J., Eitelbach F., Hummel M., Fonatsch C., Stein H.,

Eur. J. Immunol. 24:677-683(1994)

Identification of OX40 ligand and preliminary characterization of its activities on OX40 receptor

Baum P.R., Gayle R.B. III, Ramsdell F., Srinivasan S., Sorensen R.A., Watson M.L., Seldin M.F., Clifford K.N., Grabstein K., Alderson M.R.,

Circ. Shock 44:30-34(1994)

The HTLV-I protein transcriptionally modulates OX40 antigen expression

Pankow R., Duerkop H., Latza U., Krause H., Kunzendorf U., Pohl T., Bulfone-Paus S.,

J. Immunol. 165:263-270(2000)

The DNA sequence and biological annotation of human chromosome 1

Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., Bentley D.R.,

Nature 441:315-321(2006)

The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)

The MGC Project Team,

Genome Res. 14:2121-2127(2004)

4-1BB and Ox40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor kappaB

Arch R.H., Thompson C.B.,

Mol. Cell. Biol. 18:558-565(1998)

Activation of OX40 signal transduction pathways leads to tumor necrosis factor receptor-associated factor (TRAF) 2- and TRAF5-mediated NF-kappaB activation

Kawamata S., Hori T., Imura A., Takaori-Kondo A., Uchiyama T.,

J. Biol. Chem. 273:5808-5814(1998)

CD134 is a cellular receptor specific for human herpesvirus-6B entry

Tang H., Serada S., Kawabata A., Ota M., Hayashi E., Naka T., Yamanishi K., Mori Y.,

Proc. Natl. Acad. Sci. U.S.A. 110:9096-9099(2013)

The crystal structure of the costimulatory OX40-OX40L complex

Compaan D.M., Hymowitz S.G.,

Structure 14:1321-1330(2006)

Inherited human OX40 deficiency underlying classic Kaposi sarcoma of childhood

Byun M., Ma C.S., Akcay A., Pedergnana V., Palendira U., Myoung J., Avery D.T., Liu Y., Abhyankar A., Lorenzo L., Schmidt M., Lim H.K., Cassar O., Migaud M., Rozenberg F., Canpolat N., Aydogan G., Fleckenstein B., Casanova J.L.,

J. Exp. Med. 210:1743-1759(2013)